Contact

We’ve pre-built the future of cell therapy.

Pre-validated platforms and enabling technologies that accelerate the development and manufacture of your allogeneic iPSC-derived allogeneic cell therapies.

The keys to unlocking commercially viable cell therapies.

We know the science of iPSCs

We’ve been doing this, and only this, for 15 years, starting with foundational work in iPSCs up to and including breakthrough innovations in essential enabling technologies. 

Working_Icons (1)

We know the business of cell therapy manufacturing

We know how to make the economics of mainstream cell therapies work — so efficiencies can be applied, COGs can be reduced, and life-changing treatments are available to more patients 

Platforms & Technology Scientific Image 1

The platforms and technologies that make the extraordinary every day. 

From patient access and cost to product development and manufacturing challenges, there is no shortage of complexities to deal with on the way to making cell therapies into mainstream treatment options.

At Cellistic, we’ve mastered those challenges head on, investing in the platforms, technologies, and capabilities to help your program advance to its next step naturally and efficiently.

 

Pulse and Echo:
High-performance exclusively from Cellistic.

Elevator pitch Infographic simplified 1

Our Platforms

The Pulse Platform

A standardized iPSC cell line development OR CLD platform to save time and resources in the development of your own product-specific GMP master cell bank (MCB).

Checkmark IconSTAR-CRISPR™ Multiplex Editing

Checkmark IconAutomated clonal selection

Checkmark IconGMP workflows

Checkmark IconClear IP visibility (all licenses under one roof)

The Echo Platform

A pre-built differentiation and expansion platform that efficiently and economically scales banked iPSCs to drug product.

Checkmark IconFeeder free and bioreactor based

Checkmark IconBespoke, flexible capacity 

Checkmark IconEMA-certified, FDA and PMDA-compliant

Our Enabling Technologies

Allo Chassis™

Immune-cloaked iPSC cell lines derived from primary CD34 or CD4+ T-cells to fast-track development across multiple applications.

Checkmark Icon Available immediately

Checkmark Icon Clear cost structure and a single IP license

Checkmark IconEMA and FDA GMP compliant

STAR-CRISPR™

Advanced gene-editing technology with leading knock-in and knock-outs efficiencies, multiplexed editing capabilities, and large payload deliveries. 

Checkmark IconUp to 4 simultaneous edits with high Kock-In/Knock-Out performance

Checkmark Icon40% reduction in off-target effects versus traditional gene editing systems

Checkmark IconProprietary portfolio of tested targets and AI-based methods for off-target analysis

Group 35320-2

Tune our platforms and technologies to your exact needs.

The next steps are clear: You learn more about our platforms and technologies (and the experienced team behind them). We talk about your immune oncology or regenerative medicine’s specific challenges and opportunities. And then together, we chart the ideal  path to advance your program to commercial success.